Valdes Laboratories - Diagnostic Reference Laboratory

Pugia MJ, Sommer R, Corey P, Anderson L, Gleason S, Jortani SA, Elin RJ, Gopual DL, Valdes RJr. Lott JA. The uristatin dipstick is useful in distinguishing upper respiratory from urinary Tract infections. Clin Chim Acta 2004; 341:73-81.

Jortani SA, Prabhu SD, Valdes RJr. Strageties for Developing Biomarkers of Heart Failure. Clinical Chemistry 2004; 50(2):265-278.

Elbeiik T, Surtihadi J, et al, Jortani SA, et al, Valdes RJr, et al. Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCE RNA 3.0 Assay (bDNA). Journal of Clinical Microbiology 2004; 42(2):563-569.

Barreuto F, Jortani SA, Valdes RJr, Hoffman RS, Nelson LS. Cardioactive steroid from an herbal cleansing preparation. Annals of Emerg Med 2003;41(3):396-399

Keeling KL, Linder MW, Bukaveckas BL, Jortani SA, Valdes, RJr. A rigorous approach for investigation of unexpected phenytoin toxicity. Journal of Clin Ligand Immunoassay 2003;26(1):19-24

Barreuto FJr, Jortani SA, Valdes R Jr, Hoffman RS, Nelson LS. Cardioactive steroid poisoning from an herbal cleansing preparation. Annals of Emergency Medicine 2003; 41(3):396-399

Keeling KL, Jortani SA, Womack EP, Valdes RJr. Measurement of Endogenous Dihydroouabain-like Factor (Dh-OLF) in Heart Failure. Research Louisville 2003

Keeling KL, Jortani SA, Womack Jr EP, ValdesRJr. Measurement of endogenous dihydroouabain-like factor (Dh-OLF) in heart failure patients. Clin Chem 2003;49 (suppl): A-69 (Abstract C-30)

Jortani SA, Snyder JW, Valdes R.Jr. Role of clinical laboratory in dealing with Bioterrorism. Journal of the Isfahan Medical Council 2002; 12:32-38. (Translation of above, CCJ)

Valdes RJr., Jortani SA, Elin RJ, Thomas M, Womack EP, Pugia M. Point-of-Care Urinary Trypsin Inhibitor Assay (Uristatin) as an Aid in Diagnosis of Bacterial Infection. Clin Chem Lab Med 2002;40 (suppl):S-295 (Abstract W-RE-003)

Keeling KL, Jortani SA, Linder MW. Valdes RJr. Prolonged elimination half-life of phenotoin in an elderly patient also on celecoxib. Clin Chem 2002;48(6):A52 Supp.

Jortani SA, Snyder J, Valdes Jr R. Role of clinical laboratory in dealing with bioterrorism. J of Isfahan Medical Council 2002;12:32-38.

Jortani SA, Valdes R Jr. Mammalian cardenolides as biomarkers in congestive heart failure. Cardiovascular Toxicology. 2001:1;165-170.

Jortani SA. Alcohol testing near the patient. Advance Laboratory, 2001;10:10 –11.

Jortani SA, Valdes R Jr. The difference between digoxin and digitoxin is more than an "it". Clinical Toxicology News Letter. American Association for Clinical Chemistry, 2000:DEC;2-3.

Jortani SA, Snyder J, Valdes R Jr. Clinical laboratory’s role in managing terrorism with chemical and biological agents (Review). Clin Chem, 2000;46:1883-1893.

Jortani SA. Point-of-care testing for alcohol. An in-service training and continuing education program. Therapeutic Drug Monitoring and Toxicology 2000:21(5):121-126.

Valdes R Jr., Jortani SA. The current assessment of qualitative and quantitative point-of-care delivery of cardiac markers. In: Markers in Cardiology: Current and Future Clinical Applications. Adams JE III, Apple FS, Jaffe AS, WU AHB, eds. Armonk, NY: Futura Publishing Company, Inc. 2001:35-46.

Valdes R Jr., Jortani SA. Standardizing utilization of biomarkers in diagnosis and management of acute cardiac syndromes. Clinica Chemica Acta 1999;284:135-140.

Jortani SA, Pinar A, Johnson NA, Valdes R Jr. Validity of unbound digoxin measurements by immunoassays in presence of antidote (DigibindÒ). Clinica Chemica Acta 1999;283:159-169.

Apple FS, Christenson RH, Valdes R Jr., Andriak AJ, Berg A, Dhu SH, Feng YJ, Jortani SA, Johnson NA, Koplen B, Mascotti K, Wu AHB. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the Triage Cardiac Panel for detection of myocardial infarction. Clin Chem 1999;45:199-205.

Valdes R Jr., Jortani, SA. Monitoring of unbound digoxin in patients treated with anti-digoxin antigen-binding fragments: A model for the future? Clin Chem 1998;44:1883-1885.

Jortani SA, Miller JJ, Helm RA, Johnson NA, Valdes R Jr. Suppression of immunoassay results by cross-reactivity. Journal of Clinical Ligand Assay 1997;20:177-79.

Jortani SA, Trepanier D, Yatscoff RW, Valdes R Jr. Convergence of three methods to resolve discrepant immunoassay digitoxin results. Clin Chem 1997;43:1805-8.

Valdes R Jr., Jortani SA, Gheorgiade. Standards of laboratory practice: cardiac drug monitoring. Clin Chem 1998;44:1096-1109.

Jortani SA, Valdes R Jr. Antiarryhythmics in therapeutic drug monitoring and toxicology, an in-service training and continuing education program. 1997;18:259-76.

Jortani SA, Valdes R. Digoxin and related endogenous factors. Critical Reviews in Clinical Laboratory Science 1996;34:225-74.

Jortani SA, Helm RA, Valdes R Jr. Inhibition of Na,K-ATPase by oleandrin and oleandrigenin and their detection by digoxin immunoassays. Clin Chem 1996:42;1654-58.

Gupta A, Thorkelsson, Jortani SA, Valdes Jr R, Shemie S, Verjee Z, Joshi P. A case of non-digitalis cardiac glycoside intoxication. Therapeutic Drug Monitoring 1996;1977:711-14.

Jortani SA, Miller JJ, Valdes R Jr. Resolving clinically discrepant digoxin results: A case study involving multiple interferences. Journal of Clinical Ligand Assay, 1996;19:131-37.